MSA as a Serum Marker in Breast Cancer
Author Information
Author(s): S.A. Stackerl, N.P.M. Sacks, J. Golder, J.J. Tjandra, C.H. Thompson, A. Smithyman, I.F.C. McKenzie
Primary Institution: University of Melbourne
Hypothesis
Can mammary serum antigen (MSA) levels serve as a reliable serum marker for breast cancer compared to carcinoembryonic antigen (CEA)?
Conclusion
MSA levels are elevated in patients with breast cancer and may be more effective than CEA for monitoring the disease.
Supporting Evidence
- 75% of Stage I breast cancer patients had elevated MSA levels.
- 89% of Stage II breast cancer patients had elevated MSA levels.
- 93% of Stage IV breast cancer patients had elevated MSA levels.
- MSA levels correlated with the clinical course of the disease in 89% of cases.
Takeaway
This study found that a substance called MSA in the blood can help doctors see if someone has breast cancer and how it's doing, better than another test called CEA.
Methodology
Serum samples were analyzed using a competitive enzyme immunoassay to measure MSA levels.
Potential Biases
Potential bias in sample selection and the interpretation of results due to the study's design.
Limitations
The study may not account for all non-malignant conditions that could elevate MSA levels.
Participant Demographics
Included patients with breast cancer at various stages, as well as normal individuals and patients with other cancers.
Statistical Information
P-Value
p=0.025
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website